UCB Pharma To Launch Keppra-Only Pregnancy Registry In January
This article was originally published in The Pink Sheet Daily
Executive Summary
Levetiracetam registry will allow the company to access pregnancy exposure data that could also be used to support follow-on products to treat epilepsy. Patients may self-register or enroll through their health care provider.
You may also be interested in...
FDA Drug Safety Plan Expected Within Two Weeks, Outgoing HHS Secretary Says
The Administration will present a plan designed to "improve the conditions" at FDA by Dec. 17, HHS Secretary Thompson says while announcing his resignation. Thompson cites need for an "independent office of safety to look at drugs."
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.
User Fee Deal For Ad Review Funds Stems From PhRMA DTC Principles
A draft agreement between industry and FDA that would assess user fees for "advisory review" of broadcast direct-to-consumer ads prior to initial public dissemination had its genesis in the Pharmaceutical Research & Manufacturers of America's DTC guiding principles